Abstract: CD Genomics is an innovative sequencing and genotyping company. Our Disease Panel platform provides a series of proprietary, ultra-high multiplexed NGS target enrichment technology that integrates the company’s advanced panel design. The cancer panels are designed to address the practical needs of cancer-related studies. These panels are featured an innovative background cleaning technique that allows plenty of amplicons to be multiplexed in a single reaction pool, allowing a large number of cancer-related genes to be detected in a single assay. They can be designed as ready-to-use panels or as customized assays.Summary: CD Genomics is dedicated to providing the highest level of sequencing services. With various solution options and experienced scientists, we offer the most suitable strategies according to your sample and research purpose. To find more about Cancer Panels, please feel free to contact us.
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
FuGENE SI: A novel and efficient siRNA transfection reagent with minimal cellular toxicity.
Tony Larsen, Douglas Grunwald, Chris Sherrill, and James Prudent
Why Cancer Panels Stand Out for Cancer Research
WGS, WES, or Targeted Gene Panels? Choose the Best Option for Your Disease Research.
Bioinformatics And Its Application In Molecular Microbiology
How to Perform Bioinformatics Analysis for Microbial Sequencing